Actively Recruiting
Randomized Comparison of Laser Ablation and Crystallized Phenol for Primary Uncomplicated Sacrococcygeal Pilonidal Sinus Disease
Led by Sanliurfa Education and Research Hospital · Updated on 2026-09-01
120
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a single-center, randomized clinical trial to compare two minimally invasive treatments for adults with primary uncomplicated sacrococcygeal pilonidal sinus disease. The purpose is to evaluate and compare the pain experienced on the first day after treatment using laser ablation and crystallized phenol application. Additional goals include assessing healing by day 30, pain at day 7, analgesic use duration, time to resume daily activities and work, early complications, and recurrence at 6 months. Participants will be randomly assigned to one of two groups one receiving laser ablation with a Leonardo Mini 1470 nm diode laser, and the other receiving crystallized phenol application. Both groups undergo the same initial sinus preparation, which includes a small 1 cm incision, hair and debris removal, and curettage. Repeat treatment sessions may be done if needed following a secondary healing protocol. During the study, participants will be monitored for pain levels, wound healing progress, complications, and recurrence of disease. Pain scores will be recorded on postoperative days 1 and 7, and complete epithelialization will be assessed by day 30. Researchers will also track how long participants use pain medication, when they return to daily activities and work, and any local complications within 30 days. Recurrence will be evaluated at six months. The study is expected to last until March 2027 with a total of 120 participants.
CONDITIONS
Brief Title
LASER VERSUS CRYSTALLIZED PHENOL IN PILONIDAL SINUS DISEASE
Research Team
V
Vedat Kaplan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here